Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNAJessica K Lee, Mehlika Hazar-Rethinam, Brennan Decker, et al.
International Journal of Cancer|December 18, 2020
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors casesRichard S P Huang, James Haberberger, Ethan Sokol, et al.
NPJ Precision Oncology|June 17, 2025
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fractionSaumya D Sisoudiya, Hanna Tukachinsky, Rachel B Keller-Evans, et al.
JCO Precision Oncology|January 31, 2024
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to TreatmentAlessandro Russo, Jessica K Lee, Lincoln W Pasquina, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patientsSai-Hong Ignatius Ou, Leora Horn, Marcelo Cruz, et al.
JCO Precision Oncology|July 6, 2023
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessJulia C F Quintanilha, Michael H Storandt, Ryon P Graf, et al.
The Oncologist|September 30, 2016
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal CancerAndrew Rankin, Samuel J Klempner, Rachel Erlich, et al.
Clinical Genitourinary Cancer|November 17, 2023
The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate CancerWill H Jin, Liangliang Zhang, Ryon Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2023
Unique Spectrum of Activating BRAF Alterations in Prostate CancerAlex Chehrazi-Raffle, Hanna Tukachinsky, Eamon Toye, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNAJessica K Lee, Mehlika Hazar-Rethinam, Brennan Decker, et al.
International Journal of Cancer|December 18, 2020
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors casesRichard S P Huang, James Haberberger, Ethan Sokol, et al.
NPJ Precision Oncology|June 17, 2025
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fractionSaumya D Sisoudiya, Hanna Tukachinsky, Rachel B Keller-Evans, et al.
JCO Precision Oncology|January 31, 2024
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to TreatmentAlessandro Russo, Jessica K Lee, Lincoln W Pasquina, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patientsSai-Hong Ignatius Ou, Leora Horn, Marcelo Cruz, et al.
JCO Precision Oncology|July 6, 2023
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessJulia C F Quintanilha, Michael H Storandt, Ryon P Graf, et al.
The Oncologist|September 30, 2016
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal CancerAndrew Rankin, Samuel J Klempner, Rachel Erlich, et al.
Clinical Genitourinary Cancer|November 17, 2023
The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate CancerWill H Jin, Liangliang Zhang, Ryon Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2023
Unique Spectrum of Activating BRAF Alterations in Prostate CancerAlex Chehrazi-Raffle, Hanna Tukachinsky, Eamon Toye, et al.
Pageof 13